Keywords
Mesothelioma, Survival analysis. Cox hazard regression analysis, Biobanking, Risk factor
Mesothelioma, Survival analysis. Cox hazard regression analysis, Biobanking, Risk factor
We have addressed the comment to three reviewers regarding this article. We have highlighted the importance mesothelioma developing in carriers of germ-line mutations have significant improved survival.We discuss the issue environmental exposure (Natural Occurring Asbestos) and occupational exposure and their association with pleural and peritoneal mesothelioma in introduction section. We recognize that we do not have radiological analysis to support exposure and rely on self-reported data.
See the authors' detailed response to the review by Tobias Peikert
See the authors' detailed response to the review by Nico van Zandwijk
See the authors' detailed response to the review by Michele Carbone
Malignant mesothelioma is a rare and fatal malignancy, associated with occupational and environmental exposure to asbestos. As per American Cancer Society, approximately 3000 new cases are diagnosed per year in the United States. The pleura is the primary site of mesothelioma occurrence, but it also occurs at other sites (pericardium, peritoneum, tunica vaginalis testis)1,2. For pleural mesothelioma, the median overall survival age ranges from 21 months (for Stage I) to 12 month (for Stage IV) disease3. In the 1970s, the incidence of mesothelioma cases started to increase, and it became evident that the occupational and environmental exposures to asbestos (occurring during 1930s–1970s) were associated with the increased incidence of this fatal disease4. Despite regulations aimed to ban the industrial use of asbestos by US Occupational Safety and Health Administration (OSHA) in 1970, data do not suggest a decline in the incidence of malignant mesothelioma in the U.S.5. However, the impact of these changes are difficult to assess due to the fact that mesothelioma is typically diagnosed decades after the initial asbestos exposure6. A recent multisite cohort investigation reported that the median time of diagnosis from the first environmental exposure was 38.4 years (IQR 31.3–45.4 years)7. The genetics and environmental exposure plays a critical role in acquiring malignant mesothelioma. BAP1 is the only gene reported to be in a causal pathway for malignant mesothelioma development in connection with asbestos exposure. BAP1 germ line mutation has been found to be a risk factor for the development of malignant mesothelioma in families where the mutation is found in 50% of members. This mutation has also found to be linked to the development BAP1 cancer syndrome, characterized by increased incidence of malignant mesothelioma, uveal and cutaneous melanoma, and melanocytic BAP1-mutated atypical intradermal tumors8,9.
It has been reported that majority of pleural malignant mesothelioma cases in men and women are linked to the exposure to asbestos. Asbestos particle exposure is considered to be both, indoor and outdoor commercial and naturally occurring asbestos. Naturally Occurring Asbestos (NOA) concentration in soil is commonly lower then detected with light microscopy but can cause potential hazardous airborne exposure. To detect the environmental exposure to NOA is much more challenging than to identify commercial exposure to asbestos. Activity based sampling is considered to be very important for health risk assessment and to characterize the environmental exposure10,11. The other approach is to study the high risk population and screen patient with benign pleural disease through radiographic imaging. Previous research also explored the differences between the development of malignant mesothelioma in patients that had environmental exposure like NOA or have genetic risk factors in conjunction with occupational exposure (even at a low level). In the cases of malignant mesothelioma that have been linked with environmental exposure, BAP1 mutations have mainly been seen in younger population with equal sex and pleural/peritoneal distribution12,13.
After the pleura, the peritoneum is the second most frequent site of origin of mesothelioma14. The epidemiological studies of peritoneal mesothelioma are complicated by the rarity of this disease, as well as by possible geographic and temporal variations in diagnostic practices15. While survival for patients with peritoneal mesothelioma is more favorable, with patients surviving up to 60 months16,17, limited number of papers explored factors affecting the survival of peritoneal mesothelioma.
However, given the rarity of the disease, few databases have a sufficient number of cases and treatment data to make analysis of therapeutic options with statistical significance possible. NMVB is an especially valuable resource for mesothelioma research, as it includes populations residing in Pennsylvania and New York states (two of the top 5 states for mesothelioma-associated mortality)18. Previous SEER (Surveillance, Epidemiology and End Result Program) based studies exploring factors that influence mesothelioma did not include populations residing in Pennsylvania and New York19.
Previously published research of pleural mesothelioma suggested that histological type (epithelioid) and early stages were associated with improved survival with surgical treatment20. Other predictive factors explored in previously published literature including gender, advanced age, weight loss, chest pain, poor performance status, as well as low hemoglobin, leukocytosis, and thrombocytosis. It has been suggested that female patients with mesothelioma have better life expectancy as compared to male patients21.
Currently there are few therapeutic options, including surgery, chemotherapy, radiation therapy and a combination of these options that may significantly improve the overall survival from this deadly disease22. Considering the aggressive nature and poor prognosis associated with this disease, improving our existing knowledge regarding the biology of the disease and factors predictive of the efficacy of existing therapeutic options and treatment regiments for malignant mesothelioma is critical.
In this study, we analyzed malignant mesothelioma cases from the National Mesothelioma Virtual Bank (NMVB) to evaluate the effect of clinical, pathological, and epidemiological factors, and therapeutic options as determinants of overall survival. Thus our study adds geographic breadth to the existing mesothelioma research knowledge. Additionally, our dataset includes cases of peritoneal mesothelioma, which were not the focus of previous studies.
This study is conducted under the Institutional Review Board (IRB) approval (IRB #0608194) of NMVB and approval from the principal investigator of NMVB to use the de-identified data from the resource.
The patient cohort for this study (n=888) is selected from the NMVB resource, which contains both pleural and peritoneal malignant mesothelioma cases. The NMVB database only records general treatment type including cancer directed surgery alone, surgery combined with chemotherapy, as well as surgery combined with chemotherapy and radiation. The specific type of treatment (such as exact surgery type of type of chemotherapy regimen used) is not recorded in the NMVB. NMVB enrolls patients from NMVB collaborative sites (New York University, University of Pennsylvania, University of Maryland, Roswell Park Cancer Institute and University of Pittsburgh Medical Center) in the north east region of country. Thus, there may be a selection bias with patients because there are few patients enrolled from the other regions of the country due to NMVB network coverage. In addition, NMVB has developed to collect mesothelioma biospecimens and data from prospectively consented retrospectively identified patients.
Demographic, treatment, clinical and survival information of histologically confirmed pleural and peritoneal mesothelioma patients diagnosed between 1999 and 2017 were obtained from the NMVB database. Inclusion criteria included the following: confirmed diagnosis of malignant mesothelioma (limited to pleural and peritoneal presentation), presence of complete data on age, gender, race, asbestos exposure, smoking history, history of alcohol use, histological type, site of tumor, disease stage (for pleural presentation), vital status, and survival period. Exclusion criteria included the following: benign mesothelioma, and tumor site other than pleura and peritoneum. This investigation was limited to the most common histological subtypes of malignant mesothelioma including biphasic, epithelial or epithelioid, and sarcomatoid. The desmoplastic histology subtype is classified as sarcomatoid, and papillary mesothelioma as epithelial or epithelioid23,24. For the purpose of this study, the tumor anatomic site is classified into two main categories: pleura (which includes visceral/parietal pleura and lung, chest wall, ribs) and peritoneum (includes peritoneal cavity and organs involved). This analysis focused on 888 participants that met the inclusion criteria. Patient characteristics are presented in Table 1. Case selection flow is presented in Figure 1.
We have performed analysis of staging data to pleural mesothelioma cases that have surgical resections, there is no formal TNM staging system for peritoneal malignant mesothelioma. We converted the TNM staging of pleural mesothelioma into stage grouping as per College of American Pathology (CAP) protocol 2017 for pleural malignant mesothelioma. The metastatic disease status was defined as the tumor spread from the point of origin to the lymph node and other organs in the body.
We included the following variables in the analysis: age, gender, race, smoking history, history of alcohol, asbestos exposure, site of tumor, histological type, treatment, staging and outcome variables including vital status and survival period. Duration of observation was defined as time (in months) between date of initial diagnosis until death (vital status = expired) or the date of last known contact for each participant. Smoking history was analyzed as a dichotomous variable (yes/no), where current, past and smoking for a brief period of time, were grouped as positive history of smoking (yes). The contribution of the three treatment types on mesothelioma survival rate is evaluated in this study.
We constructed survival curves using the Kaplan-Meier method for the entire dataset, followed by a separate analysis limited to female patients. We also performed a separate Kaplan-Meier analysis for peritoneal cases only. We performed Log-rank test of equality across strata for categorical variables. We analyzed the independent contribution to mesothelioma survival of several prognostics with univariable and multivariable regression methods based on the Cox proportional hazards model. Variables were entered into the model using a forward selection approach, starting with the most significant variable (based on the unadjusted p-value) and then continuing in order of significance. We analyzed factors contributing to mesothelioma survival separately for cases with complete data and with missing data to rule out any systematic bias associated with cases with missing data. Two-tailed p-values less than 0.05 were considered significant. We used The R Project (version 3.4.0) for Statistical Computing to perform all analysis25.
The majority of patients were European American (97%) and male (77%). Positive history of smoking has been reported by 364 (57 %) patients among n=641 and positive history of asbestos exposure has been reported by 413 cases (78 %) among n= 531. The epithelial or epithelioid histological subtype was the most prevalent histology in this dataset (n = 636), in 71.4% of cases. Cancer directed surgery has been performed in 54 % cases, while surgery and chemotherapy treatment jointly has been administered in 37% of cases. The median overall survival of the cohort was 15 months. Table 2 and Figure 3 demonstrate the results of the univariable and multivariable analysis respectively (Cox proportional hazard regression models).
Overall, the non-parametric univariate Kaplan Meier analysis and log rank tests demonstrated longer survival in younger age group (18–44 years), female gender, with no known asbestos exposure history, epithelioid histological type, combined surgical and chemotherapy, Stage I, or peritoneum presentation (Figure 2a–2i).
The median survival for age group 18–44 years was 59 months (95% CI: 34 - 91) but much less favorable for the age group 75 and over, at 10 months (95% CI: 9 – 13). The median survival for females was 22 months (95% CI: 18 - 30) as compared to 14 months for males (95% CI: 13-16). The group with no reported history of asbestos exposure had a median survival rate of 20 months (95% CI: 16 - 31), as compared to median survival of 15 months (95% CI: 13-17) for the group with reported exposure. The epithelioid histological type median had a median survival of 18 months (95% CI: 17-21) as compared to 10 months for biphasic (95% CI: 9-13) and 7 months for sarcomatoid subtype (95%CI: 6-11). The European American group had a median survival of 15 months (95% CI: 13 – 16) as compare to median survival of 34 months (95% CI: 21-83) in non-European American population. The analysis suggests patients receiving combined therapies [(surgical and chemotherapy (95% CI: 13-19), surgical plus chemotherapy and radiation therapy (95% CI: 10-21)] had a more favorable median survival period in comparison to those with single line surgical therapy (95% CI: 8-14). Overall, median OS was most favorable (23 months (95% CI 21 to 27 months)) for patients treated with combined surgery and chemotherapy. Adding radiation to chemotherapy did not improve survival.
The median survival period for stage I group (including stages IA and IB) was 20 months (95% CI: 18 – 25) as compared to 12 months for stages III and IV. Presentation in the peritoneum site and no history of smoking was also associated with improved survival (Figure 1). When stratified by anatomic site of tumor, the median survival period among patients with peritoneal mesothelioma, who received surgical and chemotherapy, demonstrated longer survival of 28 months (95% CI: 28 – 45) as compared to 14 months (95% CI: 11 – 17) in patients with pleural mesothelioma.
Overall, multivariable analysis confirmed that younger age groups, female gender, peritoneal anatomic site, combination of surgery and chemotherapy, no history of smoking, early stage (I and II), and epithelial histology were all predictors of more favorable survival (Table 2).
In addition, we performed multivariable cox hazard proportional analysis on the complete dataset of n= 477 which had no missing record variables that has obtained from the primary dataset (n= 888). We included all the predictive prognostic variables except for stage, because there is no established TNM staging for peritoneal mesothelioma. We presented these results as supplementary analysis in Figure 3.
The focus of this study has been on the exploration of risk factors affecting mortality in the states of Pennsylvania and New York, a region with an aging population, environmental concerns, history of notable asbestos exposure, and other risk factors associated with mesothelioma development. This region has not been covered by previously reported investigations. In addition to expanding the geographic region in this study, another added value of this study is that we explored factors contributing to survival for peritoneal mesothelioma separately from the more prevalent pleural presentation. Survival analysis on the NMVB cohort demonstrated that being aged 44 and under, female gender, epithelioid histological subtype, Stage I of the disease, peritoneum anatomic site and surgical therapy combined with chemotherapy were favorable prognostic factors. This study corroborates the analysis of the SEER data by Taioli et al. suggesting that female gender, younger age, early stage, and surgery alone were all prognostic factors19. This study also corroborates previous investigations suggesting that peritoneal presentation, especially among women, is associated with longer survival26.
Consistent with the literature, our data suggests that women have longer survival in comparison to men, which may be due to factors like lower levels of smoking amongst females and/or different levels of environmental exposures21,27–30. Specifically, women may be more likely to have para-occupational exposures, which typically refer to an asbestos-exposed worker serving as a vector for the transport of fibers to the household setting and family members. Other terms used in this context include household contact, take-home exposure or domestic exposure31. Exact factors explaining survival advantage among women needs to be further investigated in future research.
Strengths of this study include the use of a very large dataset collected utilizing uniform data collection protocol. The weaknesses of this study include missing information on specific surgical treatment type in this dataset and also the fact that our exposure data is self-reported and not corroborated by radiologic analyses. We also recognize that our population may not be representative of the entire population of mesothelioma patients, as large number of patients in the general population are not good surgical candidates. Additionally, while we attempted to obtain detailed occupational exposure data for asbestos and other substances, participants’ ability to recall the duration and details of their exposure is a potential source of bias. In our future investigations, we will also focus on BAP1 mutations. We will also focus our investigation on patients who were not surgical candidates, ethnic minorities, and younger patients.
Malignant mesothelioma is a life-threatening condition that has been under investigated and is important to investigate further, considering that its mortality epidemic has not shown signs of improvement in the past several decades. Further studies are needed to evaluate screening, diagnostic, staging and treatment for various subtypes of mesothelioma.
In the future, it would be particularly interesting to identify and evaluate cases of nonsurgical mesothelioma management because many patients are not good candidates for surgery. An improved understanding of factors associated with mesothelioma morbidity and mortality may help identify high-risk groups with different occupational exposures who should be further evaluated for responsiveness to preventive and innovative management strategies for mesothelioma. The identification of these factors could help patients at risk for therapy failure who may benefit from novel interventions or avoiding treatments that are not effective or with high mortality risk. We hope our report underscored the significant value of NMVB as a national research resource open to all research community and envision that in the future, existing information repositories like NMVB will be harnessed to greater extent to investigate rare diseases like mesothelioma.
The investigator can obtain the de-identified data from National Mesothelioma Virtual Bank by submitting the letter of intent (LOI) (https://mesotissue.org/node/26). The NMVB Research Evaluation Panel (REP) is composed of extramural scientists with varied expertise including laboratory science, lung pathology, mesothelioma, and statistics (https://mesotissue.org/rep) reviews scientific merit of requests for NMVB specimens/data and makes recommendation to fulfil the request after the approval of data use agreement (DUA).
This work is funded and supported by the Centers for Disease Control and Prevention (CDC) in association with the National Institute for Occupational Safety and Health (NIOSH) Grant [5U24OH009077-11].
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Pulmonary Medicine and Thoracic Oncology
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
References
1. Carbone M, Kanodia S, Chao A, Miller A, et al.: Consensus Report of the 2015 Weinman International Conference on Mesothelioma.J Thorac Oncol. 11 (8): 1246-1262 PubMed Abstract | Publisher Full TextCompeting Interests: I have no competing interests to disclose.  Dr. Carbone full disclosure: Dr. Carbone's research is funded by grants from: NCI, DoD, V Foundation, and UH Foundation: "Pathogenesis of malignant mesothelioma", through unrestricted donations. Funders listed above have no influence in the research conducted, publications, etc. In addition, Dr. Carbone has pending patent applications on BAP1, a patent using anti-HMGB1 monoclonal antibody or other HMGB1 antibodies as a novel mesothelioma therapeutic strategy, Patent No.: 9,561,274 issued, and a patent HMGB1 as a biomarker for asbestos exposure and mesothelioma early detection Application No.: 14/123,722 Patent No.: 9,244,074. Dr. Carbone is a board certified Pathologist and provides consultation for mesothelioma expertise and diagnosis, including paid medical-legal consulting.
Reviewer Expertise: mesothelioma and asbestos, environmental carcinogenesis, gene environment interaction, cancer syndromes
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Thoracic oncology
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 3 (revision) 03 Jun 19 |
|||
Version 2 (revision) 19 Dec 18 |
read | ||
Version 1 03 Aug 18 |
read | read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)